Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note Only clinical-stage therapeutic in development for OPMD dysphagia; Phase 1b/2a (NCT06185673) ongoing: all 6 Cohort 1 subjects completed 12-month follow-up, first two Cohort 2 subjects treated, no treatment-related SAEs. Single intramuscular administration to pharyngeal muscles. Orphan Drug Designation (EU and US) plus Fast Track (US). No dated readout guidance in this filing.
Per-asset detail extracted from the 10-Q filed 2026-05-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.